Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -729.87% is 22% above its 5-year average of -939.49%, near the high end of its 5-year range (-1974.26%–-471.99%).
16.14% above its 12-month average of -870.39%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1501.71%.
EBITDA MARGIN
-729.87%
EBITDA MARGIN AVG TTM
-870.39%
EBITDA MARGIN AVG 3Y
-1158.57%
EBITDA MARGIN AVG 5Y
-939.49%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+16.14%
CURRENT VS 3Y AVG
+37.00%
CURRENT VS 5Y AVG
+22.31%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Femasys Inc.
Market Cap
$6.31M
EBITDA Margin
-729.87%
TTM Avg
-870.39%
3Y Avg
-1158.57%
5Y Avg
-939.49%
Market Cap
$6.32M
EBITDA Margin
-110.02%
TTM Avg
-99.60%
3Y Avg
-109.65%
5Y Avg
-93.07%
Market Cap
$6.43M
EBITDA Margin
-485.73%
TTM Avg
-485.73%
3Y Avg
-485.73%
5Y Avg
-485.73%
Market Cap
$6.50M
EBITDA Margin
-10.17%
TTM Avg
-10.02%
3Y Avg
-12.29%
5Y Avg
-11.98%
Market Cap
$6.07M
EBITDA Margin
-41051.94%
TTM Avg
-32118.88%
3Y Avg
-145781.05%
5Y Avg
-130042.11%
Market Cap
$6.66M
EBITDA Margin
-9012.26%
TTM Avg
-10323.55%
3Y Avg
-8965.35%
5Y Avg
-8208.29%
Market Cap
$5.91M
EBITDA Margin
-417.17%
TTM Avg
-417.17%
3Y Avg
-417.17%
5Y Avg
-417.17%
Market Cap
$5.85M
EBITDA Margin
-314.07%
TTM Avg
-394.57%
3Y Avg
-554.22%
5Y Avg
-637.29%
Market Cap
$6.75M
EBITDA Margin
-4847.72%
TTM Avg
-2918.14%
3Y Avg
-1630.06%
5Y Avg
-1069.46%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Femasys Inc. (FEMY) | $6.31M | -729.87% | -870.39% | -1158.57% | -939.49% |
| Biomerica, Inc. (BMRA)vs › | $6.32M | -110.02% | -99.60% | -109.65% | -93.07% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.43M | -485.73% | -485.73% | -485.73% | -485.73% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.50M | -10.17% | -10.02% | -12.29% | -11.98% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.07M | -41051.94% | -32118.88% | -145781.05% | -130042.11% |
| Aclarion, Inc. (ACON)vs › | $6.66M | -9012.26% | -10323.55% | -8965.35% | -8208.29% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.91M | -417.17% | -417.17% | -417.17% | -417.17% |
| Lucyd, Inc (LUCY)vs › | $5.85M | -314.07% | -394.57% | -554.22% | -637.29% |
| Co-Diagnostics, Inc. (CODX)vs › | $6.75M | -4847.72% | -2918.14% | -1630.06% | -1069.46% |
| enVVeno Medical Corporation (NVNO)vs › | $5.79M | -23296.89% | -13717.94% | -7355.60% | -5953.70% |
Gross Margin
62.0%
EBITDA Margin
-729.9%
Operating Margin
-763.9%
Net Margin
-534.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1501.71% |
| 2026-03-31 | -946.86% |
| 2025-12-31 | -542.83% |
| 2025-09-30 | -471.99% |
| 2025-06-30 | -888.58% |
| 2025-03-31 | -1536.51% |
| 2024-12-31 | -774.50% |
| 2024-09-30 | -883.52% |
| 2024-06-30 | -1927.01% |
| 2024-03-31 | -1194.49% |
| 2023-12-31 | -1974.26% |
| 2023-09-30 | -1567.49% |
| 2023-06-30 | -851.68% |
| 2023-03-31 | -963.65% |
| 2022-12-31 | -1190.07% |
| 2022-09-30 | -816.59% |
| 2022-06-30 | -802.95% |
| 2022-03-31 | -825.23% |
| 2021-12-31 | -836.40% |
| 2021-09-30 | -747.76% |
| 2021-06-30 | -507.56% |
| 2021-03-31 | -477.55% |
| 2020-12-31 | -492.38% |
| 2020-09-30 | -414.09% |
| 2020-06-30 | -660.89% |
| 2020-03-31 | -745.08% |
